mDADGAN: Predicting miRNA-Drug Response Associations Using lncRNAs and a Diffusion-Based Generative Adversarial Network
Clinical Snapshot
PICO Framework
| P — Population | miRNA-drug response datasets from four public data resources |
| I — Intervention | mDADGAN (diffusion-based generative adversarial network incorporating lncRNAs) |
| C — Comparator | Six existing miRNA-drug response prediction methods |
| O — Outcomes | AUC, AUPR, ACC, Recall, and F1-score for prediction accuracy |
Bottom Line
mDADGAN represents a significant computational advancement in predicting miRNA-drug response associations by incorporating long non-coding RNAs and addressing key methodological challenges including data sparsity and class imbalance. The method demonstrated superior performance across multiple validation metrics compared to existing approaches and successfully predicted novel associations supported by published evidence. While promising for guiding targeted cancer therapy selection, this computational tool requires prospective clinical validation before routine implementation. The integration of lncRNA data appears to enhance prediction accuracy, potentially improving personalised treatment decisions. Australian clinicians should consider this as an emerging tool that may eventually support precision oncology approaches, though current clinical decision-making should continue to rely on established biomarkers and validated predictive models until further clinical validation is completed.
Key Findings
P Value: Not reported in abstract
Effect Size: Higher performance compared to six existing methods
Primary Outcome: Superior prediction accuracy across all metrics (AUC, AUPR, ACC, Recall, F1-score)
Nnt Or Sensitivity: Improved sensitivity and specificity for miRNA-drug association prediction
Confidence Interval: Not reported in abstract
Clinical Application
Requires computational infrastructure and validated miRNA profiling capabilities Relevant to Australian precision medicine initiatives; could inform TGA drug development pathways and support PBS cost-effectiveness evaluations for targeted therapies Cancer patients requiring personalised drug therapy based on miRNA profiles
Abstract
MicroRNAs (miRNAs) are key regulators of anticancer drug response, including sensitivity and resistance. Accurate prediction of miRNA-drug response associations is important for understanding response mechanisms and guiding targeted therapy. Existing prediction methods are difficult to fully capture complex high-order biological interactions and are sensitive to data sparsity and class imbalance. In this paper, we present an miRNA-drug response association prediction method called mDADGAN by constructing a diffusion-based generative adversarial network. First, we curated a large-scale and biologically informative data set from four public data resources by aggregating functional associations to facilitate model training. Second, we built a miRNA-lncRNA-drug interaction network by integrating lncRNA into the miRNA-drug network to address data sparsity and employed heterogeneous graph convolution to extract latent features from the interactions among miRNAs, lncRNAs, and drugs. Third, we applied diffusion-based perturbation to denoise and enhance the robustness of feature representations. Finally, we performed cost-sensitive learning to optimize the objective function in an adversarial training process to address class imbalance. The experimental results on four data sets demonstrated that, compared with the existing six methods, mDADGAN achieved higher values for AUC, AUPR, ACC, Recall, and F1-score. The case study demonstrates that integrating lncRNA information effectively enhances miRNA-drug response association prediction. mDADGAN can not only accurately identify known associations in the data sets but also predict previously unreported candidate associations supported by published evidence. Overall, our method mDADGAN has the ability to identify potential miRNA-drug response associations and can provide guidance for future biological experiments to enhance experimental efficiency and reduce experimental costs.
References
- 1.Lai, W., Wang, L., Tang, C., Chen, D., & Zhong, C. (2026). mDADGAN: Predicting miRNA-Drug Response Associations Using lncRNAs and a Diffusion-Based Generative Adversarial Network. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.6c00254
Related Research
Cancer medicine
Applications of Artificial Intelligence in Cancer Diagnosis and Treatment
1 Aug 2026
Acta oncologica (Stockholm, Sweden)
User perceptions of machine learning models as decision support for colorectal cancer multidisciplinary team conferences (AID-SIM-2): a qualitative simulation study.
1 Aug 2026
Journal of breast imaging
Contrast-Enhanced Mammography for Breast Cancer Screening: A Systematic Review and Meta-Analysis
30 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service